D
Dunbar Geoffrey Charles
Researcher at Merck Serono
Publications - 18
Citations - 24875
Dunbar Geoffrey Charles is an academic researcher from Merck Serono. The author has contributed to research in topics: Major depressive disorder & Placebo. The author has an hindex of 9, co-authored 18 publications receiving 22739 citations. Previous affiliations of Dunbar Geoffrey Charles include Lundbeck.
Papers
More filters
Journal Article
The Mini-International Neuropsychiatric Interview (M.I.N.I.) : The development and validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10
David V. Sheehan,Yves Lecrubier,Kathy Harnett Sheehan,P. Amorim,J. Janavs,Emmanuelle Weiller,T. Hergueta,Ross A. Baker,Dunbar Geoffrey Charles +8 more
TL;DR: The Mini-International Neuropsychiatric Interview is designed to meet the need for a short but accurate structured psychiatric interview for multicenter clinical trials and epidemiology studies and to be used as a first step in outcome tracking in nonresearch clinical settings.
Journal ArticleDOI
The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI
Yves Lecrubier,David V. Sheehan,E Weiller,P. Amorim,I. Bonora,K. Harnett Sheehan,J. Janavs,Dunbar Geoffrey Charles +7 more
TL;DR: The Mini International Neuropsychiatric Interview (MINI) as mentioned in this paper is a short diagnostic structured interview (DSI) developed in France and the United States to explore 17 disorders according to Diagnostic and Statistical Manual (DSM)-III-R diagnostic criteria.
Journal ArticleDOI
The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability
David V. Sheehan,Yves Lecrubier,K. Harnett Sheehan,J. Janavs,E Weiller,A. Keskiner,John A. Schinka,E. Knapp,M. Sheehan,Dunbar Geoffrey Charles +9 more
TL;DR: The results supported the validity and reliability of the MINI and the application of short structured interviews in clinical and research settings is discussed.
Journal ArticleDOI
A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.
Jeffrey A. Lieberman,Dunbar Geoffrey Charles,Segreti Anthony Carl,Ragy R. Girgis,Frances Seoane,Jessica S. Beaver,Naihua Duan,David A. Hosford +7 more
TL;DR: The results support the potential benefits of TC-5619 and alpha7 nicotinic receptor partial agonists for cognitive dysfunction and negative symptoms in schizophrenia.
Journal ArticleDOI
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia
David P. Walling,Stephen R. Marder,John M. Kane,W. Wolfgang Fleischhacker,Richard S.E. Keefe,David A. Hosford,Chris Dvergsten,Segreti Anthony Carl,Jessica S. Beaver,Steven M. Toler,John E. Jett,Dunbar Geoffrey Charles +11 more
TL;DR: The results do not support a benefit of TC-5619 for negative or cognitive symptoms in schizophrenia.